News

AHA/ASA Journals13d
High Dietary Phosphate Intake Induces Hypertension and Sympathetic Overactivation Through Central Fibroblast Growth Factor Receptor Signaling
BACKGROUND: Recent studies have highlighted the deleterious role of high phosphate intake in hypertension by means of ...
Rheumatology Advisor9d
TransCon CNP Gets Priority Review for Achondroplasia
The FDA has accepted for Priority Review the New Drug Application for TransCon CNP (navepegritide) for the treatment of children with achondroplasia.
Taiwan News10d
TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial
For TransCon CNP treatment-naïve children, mean annualized growth velocity (AGV) was 9.14 cm/year, representing an increase from baseline at Week 26 of 4.23 cm/year, with an improvement in mean ACH ...
Nasdaq19d
Arvinas and Pfizer Announce Phase 3 VERITAC-2 Trial Results Showing Vepdegestrant Improves Progression-Free Survival in ESR1-Mutant Breast Cancer Patients
vs Fulvestrant in ER-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results of the Global, Randomized, Phase 3 VERITAC-2 Study" will be presented by Dr. Erika ...
Monthly Prescribing Reference17d
Sacituzumab Govitecan Meets Endpoint in First-Line mTNBC Trial
human epidermal growth factor receptor 2-negative (immunohistochemistry [IHC] 0, IHC 1+ or IHC 2+/in situ hybridization [ISH]–) breast cancer in patients who have received endocrine-based ...
Monthly Prescribing Reference15d
May 2025 Recap: Drug Pipeline Updates
BLA accepted for Priority Review Fam-trastuzumab deruxtecan-nxki (AstraZeneca and Daiichi Sankyo) Human epidermal growth factor receptor 2 (HER2)-directed antibody + topoisomerase inhibitor ...